Fate Therapeutics PE Ratio 2012-2021 | FATE

Current and historical p/e ratio for Fate Therapeutics (FATE) from 2012 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Fate Therapeutics PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Fate Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 59.00 0.00
2021-06-30 86.79 $-2.35 0.00
2021-03-31 82.45 $-2.12 0.00
2020-12-31 90.93 $-2.08 0.00
2020-09-30 39.97 $-1.84 0.00
2020-06-30 34.31 $-1.56 0.00
2020-03-31 22.21 $-1.57 0.00
2019-12-31 19.57 $-1.43 0.00
2019-09-30 15.53 $-1.31 0.00
2019-06-30 20.30 $-1.22 0.00
2019-03-31 17.57 $-1.23 0.00
2018-12-31 12.83 $-1.20 0.00
2018-09-30 16.29 $-1.24 0.00
2018-06-30 11.34 $-1.19 0.00
2018-03-31 9.76 $-1.05 0.00
2017-12-31 6.11 $-1.02 0.00
2017-09-30 3.96 $-0.94 0.00
2017-06-30 3.24 $-0.95 0.00
2017-03-31 4.55 $-1.01 0.00
2016-12-31 2.51 $-1.06 0.00
2016-09-30 3.12 $-1.11 0.00
2016-06-30 1.70 $-1.08 0.00
2016-03-31 1.80 $-1.12 0.00
2015-12-31 3.37 $-1.21 0.00
2015-09-30 5.33 $-1.25 0.00
2015-06-30 6.47 $-1.33 0.00
2015-03-31 4.89 $-1.30 0.00
2014-12-31 5.03 $-1.26 0.00
2014-09-30 5.10 $-1.25 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.616B $0.031B
Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76